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ABSTRACT: Small organic molecules that inhibit functional bacterial amyloid fibers, curli, are promising new antibiotics. Here
we investigated the mechanism by which the ring-fused 2-pyridone FN075 inhibits fibrillation of the curli protein CsgA. Using a
variety of biophysical techniques, we found that FN075 promotes CsgA to form off-pathway, non-amyloidogenic oligomeric
species. In light of the generic properties of amyloids, we tested whether FN075 would also affect the fibrillation reaction of
human α-synuclein, an amyloid-forming protein involved in Parkinson’s disease. Surprisingly, FN075 stimulates α-synuclein
amyloid fiber formation as measured by thioflavin T emission, electron microscopy (EM), and atomic force microscopy (AFM).
NMR data on 15N-labeled α-synuclein show that upon FN075 addition, α-synuclein oligomers with 7 nm radius form in which
the C-terminal 40 residues remain disordered and solvent exposed. The polypeptides in these oligomers contain β-like secondary
structure, and the oligomers are detectable by AFM, EM, and size-exclusion chromatography (SEC). Taken together, FN075
triggers oligomer formation of both proteins: in the case of CsgA, the oligomers do not proceed to fibers, whereas for α-
synuclein, the oligomers are poised to rapidly form fibers. We conclude that there is a fine balance between small-molecule
inhibition and templation that depends on protein chemistry.
■ INTRODUCTION
Amyloid fibrils are β-sheet-rich protein structures associated
with human neurodegenerative diseases, such as Alzheimer’s
and Parkinson’s.
1 The common structural element of these
fibrils is the cross-β conformation, that is, β-sheets that are
packed perpendicular to the fiber axis. Most amyloid fibrils
form via nucleation-dependent pathways that involve oligo-
meric, prefibrillar structures.
2 α-Synuclein is a 140-residue
protein involved in Parkinson’s disease, a condition that affects
2% of the population over 60 years of age.
3 The function of
α-synuclein is unknown; it is an intrinsically unstructured
protein although α-helical structure is observed in the
presence of vesicles or membranes.
4 Residues 50−100 in the
synuclein sequence appear to be the primary aggregation-
promoting region.
4 In Parkinson’s disease, the process of
aggregation of α-synuclein from monomers, via oligomeric
intermediates, into amyloid fibrils is considered to be the
disease-causative mechanism. The mature amyloid fibers
may not be the source of α-synuclein mediated cytotoxicity,
however; the transient oligomeric structures have been shown
to be toxic in vivo.
3 Synuclein fibrils accumulate in cytosolic
inclusions called Lewy bodies in the brain of Parkinson’s
disease patients.
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employs the amyloid structure for a number of functions.
6
These functional amyloid fibrils have been described in a
number of organisms spanning the diversity of cellular life. In
particular, microbial functional amyloids are major components
of the extracellular matrix that promotes biofilm formation
and other community behaviors.
6 Among these, the amyloid-
forming properties of Escherichia coli CsgA are among the
most studied.
7 The extracellular curli fibrils, a common
component of bacterial biofilms, are composed of mainly
CsgA and are attached to the surface of the bacteria through
the membrane-bound CsgB protein, which acts as a “seed” for
polymerization of CsgA.
8 CsgA is an unstructured monomeric
protein that rapidly forms amyloid fibrils both in vivo and
in vitro.
9,10 The expression of CsgA and CsgB is tightly
regulated, and specific chaperones prevent fibril formation in
the cell prior to export.
7
Inhibition of the bacteria’s ability to attach to the host
and establish bacterial biofilms is emerging as an attractive new
way to prevent bacterial infections.
11−13 A number of sub-
stituted dihydro thiazolo ring-fused 2-pyridone peptidomimet-
ics
14 (general structure 1, Figure 1) have been synthesized and
tested both in vivo and in vitro for their ability to inhibit
bacterial biofilm formation. One of these compounds, FN075
(also referred to as a curlicide) inhibits CsgA fibril formation
both in vitro and in curli-dependent biofilm assays with
uropathogenic E. coli.
15 It has also been found that FN075
inhibits in vitro fibril formation of the human Aβ peptide.
16
However, the molecular mechanism governing FN075-
mediated inhibition of amyloid fibers remains unclear. Here,
we reveal the mechanism by which FN075 inhibits CsgA
fibrillation in vitro, and surprisingly, we discover that FN075
increases the rate of α-synuclein fibrillation. Thus FN075
displays cross-reactivity with diverging activity for two different
amyloidogenic proteins. This finding illustrates the importance
of assessing cross-reactivity when small molecules are designed
to inhibit amyloid-fiber formation.
■ MATERIALS AND METHODS
Compounds. Synthetic schemes of FN075 and FN071 are
described in ref 15.
Protein Preparation and NMR Experiments. See Supporting
Information.
CsgA and α-Synuclein Fibrillation Assays. FN075 and FN071
stock solutions were prepared at 10−100 mM in dimethyl sulfoxide
(DMSO) and diluted to appropriate concentrations in 50 mM
potassium phosphate. Purified soluble CsgA was diluted to 10 μMi n
50 mM potassium phosphate. Equal volumes of compound and
protein were mixed in a 96-well black plate and incubated at 20 or
37 °C. The α-synuclein experiments were performed with continuous
agitation (using 2 mm glass beads; pH 7.4, 20 mM Tris, 140 mM
NaCl); for CsgA there was agitation every 15 min. In both cases,
thioflavin T was added to a final concentration of 20 μM, and
fluorescence was measured at 480 nm (excitation 440 nm) on Tecan
Infinite or BioTek Hybrid H4 plate reader incubators.
18 Control
experiments were performed with 0.5% or 0.05% DMSO. Background
fluorescence (samples without protein) was subtracted from the
signals at each time point. Origin 8.0 was used to fit the data to
standard sigmoidal equations to extract lag times.
19 Fibrillation curves
shown are representative from at least four replicates. Fiber seeds were
prepared as described in ref 20.
Atomic Force Microscopy (AFM). AFM measurements were
performed on a PICO PLUS 5500 microscope in tapping mode at
room temperature.
21 A silicon probe was oscillated at about 330 kHz,
and images were collected at a scan rate of 1 Hz. Samples were diluted
to approximately 5 μM protein concentration with sterile filtered
Milli-Q water and applied to freshly cleaved mica surface, incubated for
5 min, washed 3 times with Milli-Q water and dried with air flow.
Electron Microscopy (EM). Ten microliter samples from the
fibrillation studies were applied to Formvar coated 200 mesh size
copper grids, incubated for 5 min, washed with Milli-Q water, and
stained with 1% phosphotungstic acid or 1% sodium silicon tungstate.
The grids were examined with a Jeol (Tokyo, Japan) model 1230
electron microscope operated at 80 kV. Images were obtained using a
Gatan MultiScan 600W camera.
Circular Dichroism. Spectra were recorded on Jasco J-710 and
J-810 spectropolarimeters equipped with peltiers (0.1 cm quartz cuvette,
190−300 nm). Buffer was 10 mM (α-synuclein) or 2 mM (CsgA)
phosphate at pH 7.4 at 20 and 10 °C.
Size Exclusion Chromatography (SEC). Protein samples were
loaded on a Superdex 200 GL gel filtration column, which was
connected to an ÄKTA purifier at 10 °C. The column was equilibrated
with 20 mM Tris, 140 mM NaCl, pH 7.4 (α-synuclein), or with
50 mM phosphate buffer (pH 7.4) for CsgA. Elution was followed by
absorption at 220, 280, and 320 nm.
■ RESULTS AND DISCUSSION
FN075 (Figure 1) is a strategically designed small molecule
with a dihydro thiazolo ring-fused 2-pyridone central fragment
containing a peptide-like segment with a free carboxylic acid
(highlighted in red in Figure 1). The compounds within this
class are designed to mimic a small C-terminal peptide with an
extended β-sheet conformation. The ring-fused central frag-
ment provides stability to the β-sheet-like conformation, and
substituents can be introduced onto this central fragment to
mimic peptide side chain properties. FN075, which is sub-
stituted with a large naphthyl substituent and a CF3-phenyl
substituent (i.e., mimicking hydrophobic side chains), is
designed to target hydrophobic β-sheet regions in proteins.
In the related compound FN071 (Figure 1), the free carboxylic
acid substituent is exchanged for a neutral methyl ester thus
keeping the peptide-like backbone but not having a free and
charged C-terminal. FN075 potently inhibits CsgA aggregation
in vitro and curli formation in vivo.
15 To better understand how
FN075 interferes with CsgA amyloid formation, we assessed
CsgA biophysical properties in the presence and absence of
FN075. Since amyloid fibers made of bacterial and human
proteins display generic properties, we also tested the
interaction of FN075 with the human amyloid-forming protein
α-synuclein.
CsgA Fibrillation Involves an Intermediate. Fibril for-
mation is readily followed by the amyloid-specific dye thioflavin
T (ThT): the fluorescence of ThT is increased in the presence
Figure 1. Substituted dihydro thiazolo ring fused 2-pyridones (1) have
been designed and synthesized to mimic small rigid C-terminal
peptides. The peptidomimetic backbone is highlighted in red and the
possibilities to introduce substituents on this central fragment via
established methods
17 is indicated with R1−R4. This study is focused
around the compound FN075 known to be an inhibitor of functional
amyloids, curli, in uropathogenic E. coli and the analog FN071, with a
blocked C-terminal.
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22 A typical fibrillation curve has a sigmoid
shape composed of a lag phase, a growth phase and a stationary
phase. We studied the intrinsic polymerization reaction of CsgA
at 37 °C by a combination of far-UV circular dichroism (CD),
one-dimensional NMR, and ThT signals (Figure 2). The
depletion of monomers was followed by the disappearance of
NMR peaks in 1H spectra. Amyloid formation was probed by
ThT emission. Finally, changes in secondary structure were
followed by far-UV CD. At 200 nm, the random coil signal
dominates, and it is found to disappear with time. In contrast,
the signal at 220 nm is found to increase with time. There is a
striking overlap in the kinetic CD traces (at 200 and 220 nm,
respectively) with the depletion of monomer (from NMR data)
and fiber appearance (from ThT data). Combining CD, NMR,
and ThT data as a function of time reveals that the monomer
disappears prior to fiber appearance and an intermediate
species is present at transitional time points (Figure 2C,D).
FN075 Stabilizes CsgA Oligomers. Upon addition of
FN075 to CsgA at 37 °C, as expected from earlier work, fiber
formation is delayed signficantly (Figure S1, Supporting
Information).
15 However, NMR reveals that upon FN075
addition, there is rapid formation of large soluble oligomeric
assemblies as all the CsgA NMR peaks disappear (due to their
high molecular weight and slow tumbling rate) (Figure 2E).
The formation of CsgA oligomers was also confirmed by size-
exclusion chromatography (SEC) where CsgA in the presence
of FN075 migrated as molecular weights much larger than that
of monomeric CsgA (Figure 2F). Gel electrophoresis of soluble
and insoluble fractions reveals that CsgA remains in the soluble
fraction, even after long incubation times, in the presence of
FN075 (Figure S1, Supporting Information). In contrast, after
prolonged incubation in the absence of FN075, CsgA is
localized in the insoluble fraction. Analysis of the absorption pro-
perties of the content in the oligomeric peak in the SEC profile
indicates the presence of both protein and FN075. Atomic force
microscopy (AFM) images of this oligomer fraction revealed the
presence of oligomeric spherical particles (Figure 2F, inset). In
contrast, fresh CsgA elutes at 15−16 mL, which corresponds to
the elution volume of a small unstructured protein. CsgA incubated
overnight does not exhibit any SEC peaks likely due to formation of
fibers during the long incubation (Figure 2F, blue line); fibers will
be removed in the filtering procedure performed prior to gel
filtration. Thus, we conclude that inhibition of fiber formation by
FN075 is through the formation of inert soluble CsgA oligomers.
In further support of an off-pathway species, addition of preformed
FN075−CsgA oligomers to fresh CsgA monomers did not affect
CsgA fibrillation kinetics as probed by ThT (Figure S1,
Supporting Information). Faster rates of CsgA fibrillation upon
seeding with preformed CsgA fibers have been reported.
9,10
FN075 Promotes α-Synuclein Fibrillation. Next we
t e s t e dw h e t h e rF N 0 7 5c o u l da l s oi n h i b i tα-synuclein
fibrillation. In contrast to CsgA polymerization, α-synuclein
fibers form slowly with a long lag time (i.e., >20 h at 37 °C,
pH 7, with agitation). Surprisingly, we found that incubation of
unfolded α-synuclein monomers at 37 °C with FN075 results
in faster appearance of the increased ThT fluorescence. The lag
time for fibrillation decreased from 23.3 ± 2.5 h to 7.3 ± 3.5 h
for 35 μM α-synuclein upon including 1:1 molar ratio of FN075
(Figure 3A). Thus, FN075 stimulates α-synuclein fiber formation.
The effect of FN075 on α-synuclein fibrillation is dose-dependent,
and the lag time decreases as a function of FN075 concentration
(Figure 3B). The shortest lag time measured for fibrillation was
2.5 ± 0.3 h for the highest FN075 concentration.
The formation of fibrils was verified by AFM and electron
microscopy (EM): samples taken from the stationary phase
contain fibrils (Figure 3C−F). Next, we tested whether preformed
α-synuclein fibers could seed α-synuclein fibrillation. Fibers
formed both in absence and in presence of FN075 were used to
seed new α-synuclein fibers (Figure S2, Supporting Information).
In these experiments, the effect of FN075 is negligible since the
final FN075 concentration is less than 1/20th of the α-synuclein
concentration (control in Figure S2, Supporting Information). We
found that seeds from fibers formed in the presence and absence
of FN075 increase the rate of fiber formation to the same extent.
Moreover, this enhanced speed of fibrillation is similar to that
found upon addition of 1 equiv of FN075.
FN075 Triggers α-Synuclein Oligomer Formation. The
interaction between FN075 and α-synuclein was studied by
Figure 2. Time-dependent structural conversion of CsgA from
monomer to β-rich polymer. (A) Depletion of monomeric CsgA
during the fibrillation reaction probed by 1H NMR at 37 °C. The
figure is an expansion of the aliphatic region in one-dimensional
spectra. (B) Time-dependent far-UV CD acquired at 37 °C. The
spectrum at 10 °C is a reference of monomeric CsgA; fibrillation is
induced by a temperature jump to 37 °C (4.5 μM CsgA and in one
sample also 45 μM FN075). (C) Overlay of kinetic traces from NMR,
CD, and ThT fluorescence. (D) Sigmodial fits of monomer depletion
(from NMR) and fiber build-up (from ThT). The analysis reveals the
presence of an intermediate during the reaction. (E) 1H NMR
expanded in the amide region upon FN075 addition to CsgA (450 μM
FN075, 45 μM CsgA): (∗) FN075 peaks, (#) imidazole (small amount
leftover from purification). (F) Size exclusion chromatograms of CsgA
in the absence and presence of FN075. Ten micromolar freshly
isolated (black) or overnight incubated protein (at room temperature)
with 100 μM (red) or without (blue) FN075. Inset: AFM of the
oligomer fraction (red trace) (bar 200 nm).
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in the presence of 0.05% DMSO corresponds to that of an
unstructured polypeptide with a negative peak at 195 nm. Upon
addition of FN075, the negative peak at 195 nm decreases and
shifts toward 210 nm; at the same time, a distinct negative
shoulder at 220 nm appears (Figure 4A). These results suggest
that when FN075 interacts with α-synuclein, the protein
becomes more ordered. The same far-UV CD changes as
here were reported for α-synuclein alone upon temperature
increase; these changes were interpreted as formation of an
aggregation-competent partially folded intermediate with signi-
ficant β-structure.
19
1H−15N HSQC spectra acquired for 15N-labeled α-synuclein
at 10 °C show that upon FN075 addition to α-synuclein, the
cross peaks for residues 1−100 disappear (using assignments
from ref 23), while the cross peaks for residues 100−140
remain visible (Figure 4B,C). NMR diffusion experiments using
the remaining cross peaks (at 10 and 37 °C) reveal that a large
assembly with a hydrodynamic radius of about 7 nm is formed
upon FN075 addition (Table 1). This value matches the
dimensions (19 nm × 9n m× 4.5 nm) reported for regular
α-synuclein oligomers in SAXS experiments.
24 Our data is thus
consistent with the formation of a large oligomeric species
where the intramolecular interactions are mediated with the
N-terminal 100 residues, whereas the C-terminal 40 residues
are unstructured and solvent-exposed. The N-terminal residues
are missing in the spectrum as a result of the large molecular
weight of the oligomer, whereas the C-terminal unstructured
residues tumble independently of the oligomer and gives rise to
Figure 3. α-Synuclein fibrillation reaction. (A) α-Synuclein (35 μM)
fibrillation at 37 °C in the presence of 0.05% DMSO alone (blue) and
with 1:1 molar ratio FN075 (black) followed by ThT fluorescence. (B)
Lag times of α-synuclein fibrillation without and with various amounts
of FN075. Error bars come from multiple experiments (at least four
for each point); the error bar is smaller than the symbol for the point
at the highest FN075 concentration. (C, D) AFM images of structures
formed during fibrillation in the absence (C) and presence (D) of
FN075. (E, F) EM image of structures formed during fibrillation in the
absence (E) and presence (F) of FN075. Bars designate 100 nm on
the AFM and 200 nm on the EM images.
Figure 4. α-Synuclein−FN075 interaction. (A) CD spectra of 20 μM α-synuclein with 0.05% DMSO (solid line) and with 30 μM FN075 (dashed line)
5 min after mixing. (Inset) The difference CD spectrum resembles that of β-sheet structure. (B) 1H−15N HSQC spectra of 70 μM α-synuclein at 10 °C.
(C) 1H−15N HSQC spectra of 70 μM α-synuclein with 200 μM FN075 at 10 °C. Cross peaks corresponding to residues 1−100 are missing due to
formation of a large oligomeric species. Assignments
23 of residues 101−140 that remain visible in presence of FN075 are indicated in the figure.
Table 1. Dependence of Stokes Hydrodynamic Radii of α-
Synuclein on FN075 Concentration and Temperature
Estimated from NMR Diffusion Experiments at the Different
Conditions
T (°C) [αSyn] (μM) [FN075] (μM) r (nm)
10 70 2.96
10 20 60 6.49
10 20 120 7.46
37 70 2.16
37 70 200 7.21
Journal of the American Chemical Society Article
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site-directed spin labeling methods that residues 36−98 are
involved in the α-synuclein fibril core
25 and, in the presence of
membranes, residues 1−100 interact with these and adopt a
helical structure.
4
Size-exclusion chromatography (SEC) of α-synuclein−
FN075 mixtures reveals the presence of α-synuclein oligomeric
species (Figure 5A). AFM analysis of the oligomer peak reveals
the presence of spherical particles (Figure 5A, inset). Although
the NMR data indicates in essence 100% oligomeric assemblies
in the presence of FN075, SEC reveals a large fraction of
monomers in addition to the oligomer peak. Contact with the
matrix of the gel-filtration column and actual separation of
individual species can cause shifts in the equilibrium between
species.
24 It was proposed that synuclein oligomers are meta-
stable and convert to monomers upon gel filtration.
24,26 Thus,
the FN075-triggered α-synuclein oligomer may to some extent
revert to monomers upon gel filtration. The same oligomeric
peak is found upon prolonged incubation of α-synuclein in the
absence of FN075, albeit the peak is then smaller (Figure 5A).
In the FN075-treated α-synuclein sample, the oligomer peak
contains FN075 according to absorption measurements. The
exact ratio is not fully reproducible (between 5 and 25 proteins
per FN075 molecule are found in oligomers), but there are
always substoichiometric amounts of FN075 in the oligomer
peak.
FN075-Triggered Oligomers Appear Similar to Regu-
lar α-Synuclein Oligomers. Upon prolonged incubation
of α-synuclein alone at 37 °C, but prior to fiber appearance,
spherical soluble oligomers (height of 3−6 nm) are observed
by microscopy (Figure S3, Supporting Information). AFM
and EM data on α-synuclein−FN075 mixtures demonstrate
the immediate appearance of similar, on a macroscopic level,
oligomers with heights around 3−6 nm in these samples
(Figure 5B,C, see also inset in panel A).
If FN075 causes faster appearance of synuclein fibers via the
formation of synuclein oligomers, the addition of preformed
FN075−synuclein oligomers (as seeds) to monomeric
synuclein should speed up synuclein fibrillation as probed by
ThT. As expected, and in contrast to the FN075−CsgA
oligomer, the addition of seed amount (10% of total protein
concentration) of FN075−synuclein oligomers to synuclein
monomers resulted in a shorter lag time in the ThT fibrillation
curve compared with synuclein alone (Figure S4, Supporting
Information). This result suggests that the FN075-induced
synuclein oligomer is on the pathway toward fibers.
FN075 Is Monomeric in Solution. When a methyl ester is
added to the position of the peptide-like C-terminal end in
FN075 (i.e., FN071, Figure 1), the compound loses its effect
on both proteins (Figure S5, Supporting Information, NMR
synuclein FN071; Figure S6, Supporting Information, ThT
data). Thus, the peptide-like C-terminal part of FN075 is
important for its activity. Since small organic molecules often
aggregate in aqueous solution,
27 we tested this using 1D NMR
for both molecules. We found that FN075 is present as a
monomer under the conditions used for NMR measurements
between 10 and 37 °C (Table S1, Supporting Information),
whereas FN071 is highly aggregated at all conditions and no
NMR resonances from the compound could be observed. This
observation can be explained by the lack of charge in FN071
that will result in a higher tendency for aggregation compared
with the charged FN075 molecule. For FN075, the radius
extracted from NMR diffusion measurements is 0.77 nm,
which is in good agreement with the predicted molecular size
(0.72 nm).
Studies have been pursued in order to find small-molecule
inhibitors of α-synuclein fibrillation, and a range of binding
modes have been reported. For example, the anti-Parkinsonian
drug selegiline causes the formation of nontoxic amorphous
aggregates of α-synuclein.
28 Like FN075, the flavonoid
compound baicalein induces spherical α-synuclein oligomers,
but in contrast to the FN075 case, these oligomers cannot
proceed to fibers.
29 Moreover, Congo red and lacmoid molec-
ules interact as aggregates with monomeric α-synuclein and
thereby inhibit fibrillation,
27 while some natural polyphenolic
compounds were found to disaggregate preformed α-synuclein
oligomers.
30 To our knowledge, there is no other small
molecule reported with analogous effects on α-synuclein as
FN075; however, the formation of toxic α-synuclein oligomers
is accelerated by the concerted action of the 20S proteasome
and liposomes.
31
■ CONCLUSION
We discovered that a small molecule, a ring-fused 2-pyridone,
designed to inhibit functional amyloids like the bacterial curli
fibers, templates the formation of human α-synuclein fibers
associated with Parkinson’s disease. Analysis of the reaction
mechanism reveals that FN075 accelerates α-synuclein
oligomer formation, and this in turn results in faster assembly
of fibers. The FN075-induced oligomers contain polypeptides
that are structured in the N-termini but the C-terminal 40
residues remain flexible and solvent exposed. Analysis of the
effect of FN075 on the curli protein CsgA reveals that also here
the small molecule stabilizes an oligomeric form; however, for
CsgA, these FN075-induced oligomers cannot assemble into
fibers, and an inhibitory effect is observed. Our in vitro findings
imply that, despite FN075 triggering oligomers in both cases,
the output effect is either inhibition or templation. Moreover,
since FN075 has a peptide-like backbone, one may speculate
that small peptide metabolites present in vivo may have similar
(templating/inhibiting) properties. In accord, non-natural
amino acid peptides have been found to interfere with amyloid
fiber formation.
32
Figure 5. α-Synuclein oligomers. (A) SEC analysis of α-synuclein:
140 μM protein was incubated in presence of 0.5% DMSO at 37 °C
for 20 h and injected onto the column (black trace); the same amount
of protein was incubated with 300 μM FN075 for 1 h (red trace). Inset
shows an AFM image of oligomer peak from the sample with FN075
(bar 200 nm). (B) AFM of a FN075−α-synuclein mixture equivalent
to the NMR sample (Figure 4C). (C) EM of FN075−α-synuclein
mixture equivalent to the NMR sample (Figure 4C). Bars correspond
to 100 nm.
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